Diabetic Ketoacidosis for the OB/GYN

What is DKA?

  • Diabetic ketoacidosis is a metabolic derangement affecting primarily patients with type 1 diabetes mellitus:

    • Typically in response to some sort of stress, an insulin deficiency is encountered

      • Because of the insulin deficiency, glucose cannot be taken up and metabolized → hyperglycemia.

      • Starvation hormone pathways activate, increasing lipolysis in the liver → free fatty acids → ketosis and acidosis.

      • The liver also doesn’t have insulin to effect uptake of excess glucose, and actually begins a process of proteolysis and gluconeogenesis → worsening ketosis and hyperglycemia. 

      • The hyperglycemia will lead to glucosuria (loss of glucose via the urine), and will cause a further loss of free water and electrolytes → ultimately progressing to impaired renal function. 

  • DKA may also occur in a patient with type 2 diabetes, where a severe relative insulin deficiency precipitates DKA or a related condition known as hyperosmolar hyperglycemic state (HHS). 

Diagnosis of DKA

  • T1DM with a precipitating event that may cause metabolic derangement and difficulty with giving insulin therapy:

    • Infections or other acute major illness

    • A new diagnosis of T1DM

    • Non-use (accidental or purposeful) of prescribed insulin therapy

    • Use of drugs which may affect carbohydrate metabolism: steroids, terbutaline, 2nd generation atypical antipsychotic agents

    • Cocaine use

    • Malfunction of insulin pumps - less common with newer systems, but still an important contributor!

  • Presentation is usually rapid onset, <24 hours:

    • Neurologic changes - confusion, stupor, coma, seizures

    • Abdominal pain - nausea, vomiting

    • Signs of volume depletion - tachycardia, dry mucous membranes, hypotension

    • “Fruity odor” due to exhaled acetone

    • “Kussmaul respirations” in severely affected patients - compensatory hyperventilation 

  • Laboratory evaluation:

    • CBC

    • BMP, with anion gap calculation

      • DKA with the production of ketones will produce an anion-gap metabolic acidosis (more on that momentarily)

      • Pseudohyponatremia is often present: correct the Na value (Na concentration falls by 2 mEq/L for each 100 mg/mL increase in glucose)

      • Potassium: will often be normal on serum values, but DKA represents a state of significant relative potassium deficit due to urinary losses and shifting of potassium extracellularly with insulin deficiency

        • When insulin is replaced, potassium is driven back into cells and will lower serum potassium - so must be replaced alongside insulin therapy! 

    • UA/ketones

    • Serum ketones / beta hydroxybutyrate 

    • Urine and serum osmolality

    • ABG - especially if serum bicarbonate is very low, or hypoxia is noted

      • On a VBG or ABG - you’ll see low pH with low bicarbonate value → metabolic acidosis

        • Remember in pregnancy, bicarbonate is typically a little lower due to compensation for chronic respiratory alkalosis -- so be sure to look at that value closely! 

    • Investigation of underlying cause -- ie., cultures/imaging if infection suspected; A1c to assess control over time; amylase/lipase if pancreatitis suspected

Treatment of DKA

Important: most large institutions will have a DKA protocol! Check your institution’s policies/procedures and note that in some places, ICU admission will be required for various levels of DKA. We present some pearls here:

Two primary things to do:

  • 1) Correction of fluid and electrolyte abnormalities

    • Give isotonic fluid (LR or NS) to replete extracellular volume losses and stabilize cardiovascular status.

      • If in shock, will need rapid bolusing.

      • If hypovolemic but not in shock, often start with 15-20 ml/kg lean body weight per hour for a few hours, before slowing down. 

      • If euvolemic, slower fluid infusion as clinically indicated. 

        • Most protocols will call for NS as the primary fluid -- however, the chloride load of NS may actually worsen acidosis initially! 

          • Two RCTs (only one mentioned in the podcast) have been performed in adults comparing LR to NS -- finding LR had a mild trend towards faster improvement, but there were no major differences otherwise. 

          • We bring this up as that trend towards faster improvement of acidosis in pregnancy may be of particular consideration - a faster improvement of pH may improve fetal appearance on monitoring. 

    • Fluid choice is often dictated by electrolyte concentrations:

    • Potassium should also be administered as the deficit will often be present:

      • If K < 3.3, KCl should be given at 20-40 mEq/hr, often added to the saline

      • If K 3.3 - 5.3, KCl 20-30 mEq is added to each liter of fluid ongoing

      • If K > 5.3, potassium does not need to be repleted (yet). 

        • Frequent monitoring of K is required, and may often in the initial stages need to be checked on an hourly basis.  

    • Other electrolytes can be in deficit, particularly phosphate and bicarbonate. However, these should not be directly repleted in most circumstances, with the exception of the most critically ill patients. 

  • 2) Administer insulin

    • IV insulin should be given for all patients alongside potassium repletion as we already described.

      • Remember - K may look normal on the BMP, but often is in deficit!

    • Short acting insulins (aspart, lispro, or regular) are preferred at the outset; long-acting insulins should be held until patient is more stable.

      • In mod-severe disease, often start with IV bolus of regular insulin at 0.1 u/kg, followed within five minutes by an infusion of 0.1u/kg/hr. 

        • Again -- most institutions have protocols that will calculate this out for you and prevent errors in administration! 

        • The effect of these doses are to bring serum glucose down 50-70 mg/dL per hour, which is usually about as fast as it can go!

        • Once glucose is around 200 mg/dL, insulin infusion should decrease to 0.02-0.05 u/kg/hr and fluids for repletion should switch to a dextrose-containing product. 

          • If glucose falls too rapidly below 200 mg/dL, can precipitate cerebral edema/injury. 

    • Once a patient is only in mild DKA or transitioning out of it, can add longer-acting agents back.

Other considerations for pregnancy:

  • Symptoms and treatment for pregnant folks are not different!

  • DKA is unfortunately more common in pregnancy, as: 

    • insulin requirements increase rapidly, predisposing patients more often to potential deficiencies

    • There are more opportunities for decompensation: n/v early pregnancy, food aversions, preterm labor, use of steroids for FLM, UTI/pyelonephritis, social concern for “harming baby” with insulin.

  • Recall normal pregnancy physiology is respiratory alkalosis -- so a pH of 7.36 may seem normal for most patients, but can represent significant acidosis in pregnancy!  

  • Consider LR for resuscitation of the pregnant patient: potentially faster improvement of pH in the first hour of treatment due to less chloride load. 

  • Consider tighter targets for glucose control with DKA (getting to 100-150 mg/dL, rather than 200, counterbalancing this with risk of cerebral edema from overcorrection). 

  • During acute DKA - fetal status is often not reassuring! 

    • If mom’s pH is 6.9, baby’s is the same or worse -- manifests with absent variability, decelerations.

    • May take several hours to resolve 

    • DKA alone is not an indication for delivery!

      • It’s preferred to try to resolve the metabolic derangements before proceeding with delivery - better maternal and fetal outcomes with waiting than proceeding with delivery with unstable maternal condition. 

Blood Transfusion

What’s in blood anyway? 

  • Whole Blood - blood that basically contains all the following components 

    • It contains everything! Most of the time, when we donate blood, we donate whole blood 

  • Red blood cells (often called packed red blood cells) 

  • Take whole blood and centrifuge it to separate out just the red blood cells. Usually, other additives will be placed in such as citrate, dextrose, and adenine to preserve the cells and keep them alive 

    • Usually can be kept refrigerated for up to 42 days in the US, but can be frozen for up to 10 years 

    • Usually 1 unit is from 1 donor, and the idea is that 1 unit should raise the HgB by 1 point 

    • Volume is anywhere between 220-340cc, and the reason this can be different is because it depends on the original HCT of the donor. Most of the time, it is about 250cc.

  • Why do we use it? 

    • Because one needs blood!

      • Should be considered in patients who have acute blood loss anemia, who are symptomatic 

        • Usually can start to think about it if Hgb is <8 g/dL, when not at baseline for patient, and if they are symptomatic 

        • Would recommend if <7 g/dL if they are postpartum or postoperative or wound healing

    • In other cases (ie. sickle cell disease), transfuse to a threshold to prevent sickle crisis 

  • Things to know before transfusion

    • Before transfusion, someone should be typed and crossed so that they get blood that matches their own 

    • If they don’t, their bodies can create antibodies against the donated blood, which can then lead to alloimmunization 

    • This is a problem for future pregnancies possibly! See our episodes on alloimmunization

    • The only exception: massive transfusion or exsanguination protocol when there is no time to type and crossmatch someone 

    • Some people will still have a fever or small allergic reaction to blood - which is why most people are predosed with Tylenol and Benadryl, but we’ll talk more about this in risks/benefits of blood transfusion 

  • Different types of pRBC 

    • Irradiated red cells - indicated for patients at risk of transfusion-associated graft-versus host disease. Components are irradiated by gamma or X-rays within 14 days of donation. Shelf life is about 14 days after irradiation 

    • Washed red cells - for patients who have recurrent or severe allergic reactions to red cells. Also for patients with IgA deficiency with anti-IgA antibodies if red cells from IgA deficient donor is not available. Shelf life is 14 days from washing 

    • CMV negative red cells - only from donors who are known CMV negative. Required for newborn babies because CMV can be fatal 

  • Platelets 

    • How do we get them? 

      • Whole blood donation → centrifuged and the buffy coats (between the red cells and plasma layers are pooled from a few donations to the plasma of one of the donors 

        • Usually, this will result in “pooled platelets” or “platelet packs” so when you transfusion a unit of platelets, it’s actually considered a “4 pack” or “6 pack” or even “10 pack” of platelets. Check with your institution. 

        • Usually, volume is about 300cc, and can be stored at room temperature (20-24 degrees C) with constant agitation 

        • Shelf life is about 5 days 

      • Apharesis donation - platelets come from 1 donor and is apheresed (separated) immediately

        • Will results in only 1 donor per pack of platelets 

        • Volume is around 200cc 

        • Again, can be stored at room temperature with agitation and lasts 5 days 

    • Why do we use it? 

      • Usually when there are low platelets 

      • Most places will have thresholds, ie. if platelets are <50K and patient needs urgent or emergent surgery or are actively bleeding 

      • Some places may put threshold for transfusion of <100k if CNS bleed

      • If not bleeding, generally consider if Plt <10k to prevent spontaneous bleed 

        • If coagulopathy but not bleeding, can consider higher threshold, around 20-30K 

    • Other things to know 

      • Platelets still need to be crossmatched to ABO and Rh antigens 

    • Different types of platelets 

      • Irradiated platelets - same reason to give these as irradiated red cells 

      • Human leucocyte antigen (HLA)-selected platelets 

      • Human platelet antigen (HPA) -selected patients 

        • Population to keep in mind: pregnant patients with neonatal alloimmune thrombocytopenia - where their antibodies attack baby’s platelets 

        • These types of platelets should be used to transfuse babies with NAIT 

  • Plasma (sometimes referred to as fresh-frozen plasma) 

    • How do we get it? 

      • Plasma is from whole blood donation or component donation by apheresis 

      • Usually frozen soon after collection to maintain activity of blood-clotting factors 

      • Can be stored for up to 3 years 

      • Thawed FFP can be stored for 24 hours 

    • Why do we use it? 

      • Contains ALL clotting factors, but the amount will depend on the amount from the donor 

      • Volume of usually 250-300cc 

      • Can be given to patients who have coagulopathy, or whom are bleeding and need massive blood transfusion 

      • Should replace 1:1:1  

  • Cryoprecipitate 

    • How do we get it? 

      • Thawing FFP to about 4 degrees C, which will produce a cryoglobulin rich in fibrinogen, Factor VIII, and von Willebrand Factor. It does NOT contain all clotting factors 

      • Usually single-donor packs or pools 

    • Why do we use it? 

      • Originally developed for treatment of hemophilia

      • It is more concentrated and lower volume than FFP. 1 pack is about 50cc 

      • Consider giving if patient is coagulopathic but also fluid overloaded 

    • Other things about it 

      • Should be stored frozen 

      • Shelf life of about 3 years 

  • Granulocytes 

    • Not going to talk about this one as much, but essentially contains neutrophils 

    • Controversial but sometimes used for patients with life-threatening conditions where they have low neutrophil counts 

  • Human albumin solution 

    • No clotting factors or blood group antibodies, so crossmatching not needed 

  • Clotting factor concentrates 

    • Can be single factor concentrates 

    • Used for treatment of inherited coagulation issues (ie. for hemophilia A, can use recombinant Factor VIIIc) 

    • PCC or prothrombin complex concentrate (PCC) contains factors II, VII, IX, and X. 

  • Immunoglobulin solutions

    • Usually manufactured from large pools of donor plasma

    • Contains antibodies to viruses that are common in the population (ie. IVIG) 

    • Specific immunoglobulins can be made from selected donors with high antibody levels (ie. Anti-D immunoglobulin or Rhogam!) 

Benefits, Risks, and Safety

  • Benefits - and how to safely give blood 

    • As discussed before, blood transfusion can be life saving in many people, but we need to do this safely  

    • We already discussed: type and crossmatch blood 

      • Right patient, right blood, right time → correct patient identification, good documentation and communication, and monitoring of the patient 

      • Patient consent needs to be obtained 

      • Also, do not give more blood than is indicated!  

  • Risks 

    • Mostly morbidity and mortality from blood transfusion is preventable, but can still occur, especially when wrong blood is given 

    • Non-infectious risks

      • Febrile non-hemolytic transfusion reactions (usually mild) - can sometimes be treated with benadryl/Tylenol pretreatment 

      • Allergic reaction - can be mild (ie. urticaria) to severe (angioedema or anaphylaxis) 

      • Acute hemolytic transfusion reaction - usually due to ABO incompatibility 

      • Bacterial contamination of blood - can lead to sepsis 

      • Transfusion-associated circulatory overload (TACO) - worsening pulmonary edema within 6 hours of transfusion 

      • Transfusion-related acute lung injury (TRALI) 

        • Caused by antibodies in donor blood reacting with patient’s neutrophils, monocytes, or pulmonary endothelium 

        • Can lead to leaking of plasma into lung alveolar spaces → cough with frothy sputum, shortness of breath, hypotension, fevers

        • Usually presents within 2 hours of transfusion 

        • CXR will show bilateral nodular shadowing in lungs 

        • Can be confused with acute heart failure, but should not be treated with diuretics 

        • May need to intubate. Supportive care for treatment 

  • What to do about acute reactions? 

    1. Stop the transfusion and undergo rapid assessment of vitals, and make sure to check patient ID and blood ID (does it match?) 

    2. Usual evaluation of ABC (airway, breathing, circulation) 

    3. If mild reactions (ie. isolated temperature of >38 degrees, pruritis, or rash), can consider treatment, but could continue transfusion 

    4. However, if increasing temperature >39, life-threatening changes (ie. allergic reaction with anaphylaxis), stop immediately and proceed to resuscitate as needed 

  • Infectious risks 

    1. Viral infections - risks are incredibly low because every blood donation is screened for HBV, HCV, HIV, HTLV, syphilis, west nile virus, Zika

    2. Every first time donor is tested for Chagas disease 

    3. Creutzfeldt-Jakob Disease - prion disease that first appeared in the UK in 1996. People cannot donate if they have:

      1. Been in UK >3 months from 1980-1996.

      2. Diagnosed with vCJD, or

      3. Had blood transfusion in UK, France, or Ireland from 1980 to present.

What if your patient declines blood transfusions?

  • Respect the values, beliefs, and cultural backgrounds of all patients 

  • Frank discussion with patients about blood transfusion and components of blood 

    • Jehovah’s Witness patients usually will refuse transfusion of whole blood and primary blood components (ie. red cells, platelets, white cells, and plasma) 

    • However, some may accept derivatives of primary blood components (ie. albumin, cryo, clotting factors, immunoglobulins) 

  • Discussion of how to save blood cells and discuss other methods of decreasing likelihood of transfusion 

    • Intraoperative cell saver, apheres, dialysis, or cardiac bypass are usually ok 

    • Iron transfusions if needed prior to procedures, if there is time 

    • Discussion of autologous transfusion if possible 

  • Signing advance decision documents (usually most hospital will have these) about which blood products are acceptable and which are not 

  • Remember: 

    • Emergency or critically ill patients with temporary incapacity must be given life-saving treatment (including blood transfusion) unless there is clear evidence of prior refusal 

What Your Charge Nurse Wants You to Know: Feat. Julie Park, RN

It’s July, and with everyone moving up into new roles, we thought we’d think a bit about our nursing colleagues!

Today, we welcome Julie Park, an assistant nurse manager and labor and delivery charge nurse at the University of Washington Medical Center. She tells us a bit about her career in nursing, what a charge nurse is and what they do, and offers some tips for success for L&D clinicians and nurses of all experience levels.

Sickle Cell Disease & Pregnancy

What is sickle cell disease?

  • Sickle hemoglobin (HbS) results from a point mutation in the beta hemoglobin gene. 

  • Sickle hemoglobin disease results from inheritance of at least one sickle mutation, and co-inheritance of another beta-hemoglobin modifying gene.

    • Classically, this is homozygosity for HbS genes (HbSS); however, sickle disease also manifests with co-inheritance of hemoglobin C (HbSC); beta-thalassemia; and others.

  • The disease causes significant pain crises and multi-system disease, thought to arise primarily from hemolytic anemia as well as vaso-occlusion.

    • Importantly from an infection perspective, splenic infarction is common early in life and thus results in a hyposplenic, immunocompromised state. 

    • Manifestations of disease can be seen in:

      • Infection, particularly a susceptibility to pneumonia and a related but indistinguishable complication known as acute chest syndrome

      • Anemia

      • Pain from vaso-occlusive crisis

      • Stroke and myocardial infarction

      • Renal disease

      • Retinopathy (particularly with HbSC disease)

      • Pregnancy complications, including growth restriction, preeclampsia, stillbirth, and maternal mortality. 

Who should be screened, and how?

  • Screening for sickle trait and sickle cell disease is now part of universal newborn screening in all 50 US states. 

  • Screening in adults is done via hemoglobin electrophoresis.

  • Screening should be offered if:

    • A partner is known to have sickle cell disease, and the other partner does not know their carrier status, or;

    • A patient does not know their carrier status and wishes to know.

      • IMPORTANT: race/ethnicity-based screening is ineffective and problematic in identifying at-risk individuals, and thus anyone who desires testing should be offered it! 

        • ACOG PB 78 on hemoglobinopathies in pregnancy, updated in 2007, notes that “ethnicity is not always a good predictor of risk,” though focuses to a large degree on observed ethnic group differences.

        • Similarly, ACOG CO 691 endorses hemoglobinopathy screening via CBC for all women, and electrophoresis for women “suspected of hemoglobinopathy based on at risk ethnicity” 

        • Other ACOG guidance now endorses offering hemoglobinopathy screening universally, including the ACOG FAQ document for patients on carrier screening. 

      • However, there are risks to screening that your patients should be made aware of, particularly with respect to genetic discrimination. 

        • Health insurance markets and employer-based plans are prohibited from this through the Genetic Information Non-Discrimination Act (GINA).

        • These protections do not extend into: 

          • life, disability, or long-term care insurance markets,

          • employers with fewer than 15 employees

          • US military and the TRICARE health system

          • the Indian Health Service

          • the Veterans Health Administration

          • Federal employees Health Benefits Program. 

    • A quick plug here for licensed genetic counselors – they are awesome and know lots of things, as well as when your patients may benefit from different types of screening! If you have access, we totally recommend listening in on a counseling session with them! 

What should be done to optimize pregnancy in the preconception period for those with sickle cell disease?

  • Most pregnancies can be managed successfully and result in live birth, with proper surveillance and preparation. 

  • Partner screening is recommended if status is not known, as we previously mentioned, as the likelihood of the fetus having a hemoglobinopathy can be 0% (if partner is not a carrier) or 50% (if the partner is a carrier). 

    • This can also help to inform approach to prenatal genetic testing and subsequent decisions for the pregnancy, if desired. 

  • Baseline preeclampsia screening 

    • Hypertension may be present due to renal disease in pregnant patients, and sickle nephropathy can result in significant proteinuria. 

    • Baseline 24 hour urine protein, in addition to LFTs, BUN, and creatinine, are useful. 

  • Ophthalmologic screening for retinal disease, which has a tendency to worsen in pregnancy

  •  Hemoglobin and iron studies 

    • Frequently, due to hemolysis, those with sickle disease are severely iron-overloaded and should potentially delay pregnancy until they receive chelation therapy (which cannot be given in pregnancy).

      • Prenatal vitamins with iron should be avoided in this particular group.

  • Baseline urine culture as asymptomatic bacteriuria and UTIs are more common in sickle disease, and are often more difficult to treat due to renal disease. 

  • Pulmonary function tests can be considered, as those with particularly severe sickle cell disease are at higher risk of pulmonary embolus and reactive airway disease, in addition to having a baseline to reference for acute concern for acute chest syndrome. 

    • Echocardiography may also be useful in severe cases to assess for underlying pulmonary hypertension. 

  • Type and screen is often one of the most important tests:

    • Often due to a history of transfusion, multiple antibodies may be present on screening, which can be significant for alloimmunization of the fetus and hemolytic disease of the fetus/newborn (HDFN).

      • If the patient is positive for an offending antibody, this will allow for partner testing to occur to determine if a fetus may be at risk for HDFN.

  • Medication Management:

    • Hydroxyurea: is generally a mainstay of sickle cell disease management in the nonpregnant patient which works by increasing Hemoglobin F production. Gamma globulin is not affected by sickling, so decreased overall concentration of HbS  

      • Regrettably in the peri-conception period, there is not much data regarding its use – but guidelines recommend discontinuing in the three months prior to conception, though the limited data that exists suggest there is no increase in major anomalies. 

    • Folic acid: due to increased red cell turnover, generally there is consensus that folate supplementation should be higher in those with sickle cell disease; 4mg daily is recommended (versus the 0.4mg – 0.8mg/day recommended universally).

    • Iron chelators: should be discontinued for conception, as they are associated with some risk of anomalies.

    • Antihypertensive medications: often patients with SCD may be taking ACE-Is or ARBs, as they are renal protective. However, these are teratogenic and should be replaced with agents that are safe in pregnancy. 

    • Pain medication: opioids are standard of care for management of severe pain in sickle cell disease. Patients who are on standing doses of opioids should be counseled with regards to risk of neonatal abstinence syndrome but should not routinely discontinue their pain medications.

      • Acetaminophen, non-medicinal strategies for pain control are also appropriate.

      • Short courses of NSAIDs may be appropriate in some circumstances, but generally are avoided in pregnancy. 

      • Aspirin in low dose should be considered in pregnancies of patients affected by sickle cell disease to help reduce preeclampsia risk.

    • Anticoagulation: patients with sickle cell disease are not typically on anticoagulants just for sickle disease; though with a history of DVT/PE, they might be, and in those cases you should treat them like other patients with that history. 

      • Absent a high-risk DVT/PE history, pharmacologic thromboprophylaxis should just be considered with any hospitalization given the high risk of clotting. 

  • Immunizations: should be up to date, and also remember due to functional hyposplenism, additional vaccines should be considered: meningococcal, pneumonia, and H. influenzae type b are all recommended for patients with sickle cell disease. 

  • Breastfeeding: should still be encouraged! Resumption of hydroxyurea use may be delayed with breastfeeding, as its not well studied in terms of its effects on infants. 

Pain crises in pregnancy – how to manage them?

  • Avoid triggers for pain crises as best as possible – dehydration, hypoxia, acidosis, infection, and cold temperatures are all common triggers. 

    • Termination of pregnancy and delivery/postpartum are two common times for pain crisis development – so appropriate hydration and monitoring are key at those time points!

    • With crisis, one key management point is reversal/correction of the trigger – and in or out of pregnancy, hydration is often key to that.

    • Oxygen therapy is often also needed due to inadequate oxygen delivery during vaso-occlusive crisis. 

  • In crisis, pain control should be aggressive!

    • Opioids are the therapy of choice, if acetaminophen is not satisfactory.

    • The patient’s experience, and their hematologist’s knowledge of the patient, are often of significant benefit in these situations! 

  • Keep your diagnostician hat on!

    • Pain crises can often be part of, or proceed significant events for patients with sickle cell disease – including DVT/PE, acute chest syndrome, or stroke. 

      • Each complication of sickle cell disease could be a podcast of management on its own – so a multidisciplinary approach is often required to ensure good patient outcomes. 

      • If patient or family is telling you the pain is different – listen! This can be a clue that something else is going on than usual pain crisis.

      • Use your hematology colleagues to guide, but often management will consist of at least CBC, chemistry panel with LFTs, and a chest xray. 

Acute Chest in Pregnancy - ACS is the leading cause of death in SS disease 

  • Often preceded by a vaso-occlusive pain episode, present with chest, arm, and leg pain consistent with a pain crisis, and follow a much more severe clinical course, often requiring mechanical ventilation, and sometimes resulting in death

  • Dx = radiographic evidence of consolidation + one of the following: 

    • Temperature >38.5C 

    • >2% decrease in O2 sat 

    • Tachypnea 

    • Intercostal retractions, nasal flaring, or use of accessory muscles 

    • Chest pain 

    • Cough 

    • Wheezing 

    • Rales 

  • Treatment: a lot of this overlaps with pain crisis:

    • Treat pain 

    • Fluids - prevent hypovolemia 

    • O2

    • Blood transfusion - discuss with heme about simple vs exchange transfusion 

    • Bronchodilators 

    • Antibiotics - usually empiric to cover things like C. trachomatis, strep, and H.flu. Usually a third gen cephalosporin with a macrolide (ie. CTX + azithromycin) 

    • Escalation of care - may need to go to the ICU! 

Asthma

Asthma is a common disorder of the lung where inflammation causes the bronchi to swell and narrow the airways (ie. bronchospasm) . This leads to reversible, recurrent airway obstruction. Symptoms include wheezing, shortness of breath, or difficulty breathing, which are often associated with “triggers” → at night, during exercise, with allergens (ie. infection, animals, mold, smoking, pollen, etc).

Let’s talk through asthma and how to treat it!

  • How do I diagnose asthma? 

    • History - wheezing, cough, shortness of breath, chest tightness; temporal relationships and triggers 

    • Physical - wheezes on auscultation 

      • Should be confirmed by demonstrating airway obstruction on spirometry that is at least partially reversible 

      • Pulmonary function tests!

  • FEV1 forced expiratory volume in 1 second

    • >12% increase in FEV1 after bronchodilator = asthma

  • FVC forced vital capacity (basically all the air that you can breathe out) 

  • Normal FEV1/FVC ratio is around 75%, but predicted normal values can be calculated based on age, sex, and height

    • Asthma is an obstructive process, so FEV1/FVC ratio will be reduced

      • This is opposed to a restrictive process, where the FEV1/FVC ratio is not reduced, but both FEV1 and FVC ARE reduced about equally)

  • How does asthma change in pregnancy / why do we care about it in pregnancy? 

    • Oxygen is good for everyone!

      • Goal is adequate oxygenation of the fetus and prevent hypoxic episodes in pregnant person 

    • Poorly controlled asthma may be associated with increased prematurity, need for C/S, preeclampsia, growth restriction, other perinatal complications, and maternal morbidity/mortality 

  • How do I classify asthma?

ACOG PB 90

  • How do I treat asthma? 

    • In general: 

      • Avoid factors that precipitate attacks (ie. allergens, smoke, pollen) 

      • Get consultants on board if complex or difficult! (i.e., medicine/pulmonary)

    • Mild intermittent asthma - albuterol as needed, no daily meds 

    • Mild persistent asthma - add low dose inhaled corticosteroids 

      • Additional alternatives that could be considered are things like Cromolyn, leukotriene receptor antagonist, or theophylline 

    • Moderate persistent asthma - add long-acting beta agonist (i.e., salmeterol) alongside low dose inhaled corticosteroid / increase to medium-dose inhaled corticosteroid (if needed) / medium-dose inhaled steroid and salmeterol 

    • Severe persistent asthma - High-dose inhaled corticosteroid and salmeterol, and if needed, oral corticosteroid 

@AmbCareRx

  • Assessment of acute asthma

    • Medical history and exam (as always) 

    • Examine airway function and fetal well-being if after 24 weeks 

    • Patients with FEV1 measurements >70% for >60 minutes can usually be discharged if not in distress

    • Can order VBG if you want to get a gas, and can likely keep in ED for treatment if FEV1 <70% but >50%  

    • However, if FEV1 <50%, may need admission 

    • If patient becomes more drowsy, poor response, severe symptoms, confusion or PCO2>42mmHg, this may be a reason to admit to ICU 


  • Treatment of acute asthma (in ED or in OB triage) 

    • Oxygen for saturation >95%; measure spirometry at bedside with respiratory therapy.

    • Inhaled short-acting beta2 agonist by nebulizer or metered dose inhaler 

    • Oral systemic corticosteroid if no immediate response.

      • If patients have FEV1 that is <40%, may need high dose inhaled short-acting beta2 agonist + ipratropium by nebulizer every 20 minutes or continuously for 1 hour and oral corticosteroids 

    • If impending respiratory arrest - intubation and mechanical ventilation — get critical care, pulmonary, and/or anesthesia on board!

    • If improved / discharging: short-acting inhaler (i.e., albuterol) 2 puffs every 3-4 hours as needed and oral corticosteroids 40-60mg for 3-10 days. No need for tapering the steroid!

      • Ensure post-discharge follow up within 1 week!